@article{pichichero_comparative_2005,
	title = {Comparative {Trial} of the {Safety} and {Immunogenicity} of {Quadrivalent} ({A}, {C}, {Y}, {W}-135) {Meningococcal} {Polysaccharide}-{Diphtheria} {Conjugate} {Vaccine} {Versus} {Quadrivalent} {Polysaccharide} {Vaccine} in {Two}- to {Ten}-{Year}-{Old} {Children}},
	volume = {24},
	issn = {0891-3668},
	url = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=ovftg&AN=00006454-200501000-00010},
	abstract = {Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135)., Methods: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples., Results: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P {\textless} 0.001 for all comparisons). This significant difference persisted through 6 months., Conclusions: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine., (C) 2005 Lippincott Williams \& Wilkins, Inc.},
	number = {1},
	urldate = {2014-09-13},
	journal = {Journal January 2005},
	author = {Pichichero, Michael and Casey, Janet and Blatter, Mark and Rothstein, Edward and Ryall, Robert and Bybel, Mike and Gilmet, Gregory and Papa, Thomas},
	year = {2005},
	pages = {57--62},
}

{"_id":"RJwj4ea3jKYd4oFwW","bibbaseid":"pichichero-casey-blatter-rothstein-ryall-bybel-gilmet-papa-comparativetrialofthesafetyandimmunogenicityofquadrivalentacyw135meningococcalpolysaccharidediphtheriaconjugatevaccineversusquadrivalentpolysaccharidevaccineintwototenyearoldchildren-2005","author_short":["Pichichero, M.","Casey, J.","Blatter, M.","Rothstein, E.","Ryall, R.","Bybel, M.","Gilmet, G.","Papa, T."],"bibdata":{"bibtype":"article","type":"article","title":"Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children","volume":"24","issn":"0891-3668","url":"http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=ovftg&AN=00006454-200501000-00010","abstract":"Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135)., Methods: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples., Results: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P \\textless 0.001 for all comparisons). This significant difference persisted through 6 months., Conclusions: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine., (C) 2005 Lippincott Williams & Wilkins, Inc.","number":"1","urldate":"2014-09-13","journal":"Journal January 2005","author":[{"propositions":[],"lastnames":["Pichichero"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Casey"],"firstnames":["Janet"],"suffixes":[]},{"propositions":[],"lastnames":["Blatter"],"firstnames":["Mark"],"suffixes":[]},{"propositions":[],"lastnames":["Rothstein"],"firstnames":["Edward"],"suffixes":[]},{"propositions":[],"lastnames":["Ryall"],"firstnames":["Robert"],"suffixes":[]},{"propositions":[],"lastnames":["Bybel"],"firstnames":["Mike"],"suffixes":[]},{"propositions":[],"lastnames":["Gilmet"],"firstnames":["Gregory"],"suffixes":[]},{"propositions":[],"lastnames":["Papa"],"firstnames":["Thomas"],"suffixes":[]}],"year":"2005","pages":"57–62","bibtex":"@article{pichichero_comparative_2005,\n\ttitle = {Comparative {Trial} of the {Safety} and {Immunogenicity} of {Quadrivalent} ({A}, {C}, {Y}, {W}-135) {Meningococcal} {Polysaccharide}-{Diphtheria} {Conjugate} {Vaccine} {Versus} {Quadrivalent} {Polysaccharide} {Vaccine} in {Two}- to {Ten}-{Year}-{Old} {Children}},\n\tvolume = {24},\n\tissn = {0891-3668},\n\turl = {http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=ovftg&AN=00006454-200501000-00010},\n\tabstract = {Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135)., Methods: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples., Results: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P {\\textless} 0.001 for all comparisons). This significant difference persisted through 6 months., Conclusions: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine., (C) 2005 Lippincott Williams \\& Wilkins, Inc.},\n\tnumber = {1},\n\turldate = {2014-09-13},\n\tjournal = {Journal January 2005},\n\tauthor = {Pichichero, Michael and Casey, Janet and Blatter, Mark and Rothstein, Edward and Ryall, Robert and Bybel, Mike and Gilmet, Gregory and Papa, Thomas},\n\tyear = {2005},\n\tpages = {57--62},\n}\n\n","author_short":["Pichichero, M.","Casey, J.","Blatter, M.","Rothstein, E.","Ryall, R.","Bybel, M.","Gilmet, G.","Papa, T."],"key":"pichichero_comparative_2005","id":"pichichero_comparative_2005","bibbaseid":"pichichero-casey-blatter-rothstein-ryall-bybel-gilmet-papa-comparativetrialofthesafetyandimmunogenicityofquadrivalentacyw135meningococcalpolysaccharidediphtheriaconjugatevaccineversusquadrivalentpolysaccharidevaccineintwototenyearoldchildren-2005","role":"author","urls":{"Paper":"http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=ovftg&AN=00006454-200501000-00010"},"metadata":{"authorlinks":{}},"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero/robin.marlow","dataSources":["ix72eqAAMGCuupBaz"],"keywords":[],"search_terms":["comparative","trial","safety","immunogenicity","quadrivalent","135","meningococcal","polysaccharide","diphtheria","conjugate","vaccine","versus","quadrivalent","polysaccharide","vaccine","two","ten","year","old","children","pichichero","casey","blatter","rothstein","ryall","bybel","gilmet","papa"],"title":"Comparative Trial of the Safety and Immunogenicity of Quadrivalent (A, C, Y, W-135) Meningococcal Polysaccharide-Diphtheria Conjugate Vaccine Versus Quadrivalent Polysaccharide Vaccine in Two- to Ten-Year-Old Children","year":2005}